News & Events
2022-10-02: Co-Development Agreement using AI Drug Discovery between Samjin Pharm. and Cyclica
news source:https://cyclicarx.com/press-releases/co-development-agreement-using-ai-drug-discovery-between-samjin-pharm-and-cyclica/
Seoul, South Korea and Toronto, Canada – Samjin Pharmaceuticals Co., Ltd. (“Samjin”; CEO, Yong Ju Choi) a pharmaceutical company devoted to develop innovative drugs to treat diseases with high unmet medical needs, and Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance arobust and sustainable drug discovery pipeline announced today a co-development agreement for drug discovery.
Under the co-development agreement, Samjin will propose novel protein targets for drug discovery to Cyclica, and Cyclica will work to discover drug candidates to the proposed targets using its proprietary, AI-enabled, drug discovery platform. Samjin will carry out the experimental validation and take the lead in further developing/commercializing the most promising drug candidate compounds.
Photo: Samjin-Cyclica Collaboration Agreement for AI Drug Discovery; Left) Naheed Kurji (CEO of Cyclica), Right) Soo Min Lee (Head of Samjin Pharm Research Center)
Soo Min Lee PhD, Head of Samjin Pharm Research Center, said “We can rapidly expand our drug research pipelines and lower the cost and time required to develop a new drug by utilizing Cyclica’s AI-based drug discovery platforms from this research collaboration. We will continue expanding our network of research collaboration with other companies or research institutes in order to develop innovative drugs efficiently.
“Cyclica’s unique ability to advance drug discovery programs for targets across the entire proteome, in combination with Samjin’s expertise in proposing novel targets, has tremendous potential. We look forward to progressing this exciting collaboration, collectively working to drug the undruggable” says Naheed Kurji, CEO, Co-Founder and President of Cyclica.
Cyclica has partnered with multiple biotech and pharma companies worldwide and have recently been named by Business Insider as a top biotech company set to take off in 2022.
